Sign up Australia
Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals’ leaping share price attracts ASX speeding ticket

Estimated size of the osteoarthritis treatment market is US$5 billion per annum.
rising share price chart
Positive osteoarthritis trial results revealed last month

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has attracted a speed and volume ticket from the ASX following an increase in its share price from a low of 72.5 cents to an intraday high of 90 cents on Friday.

Responding to the price and volume query, the company said that there was no information that had not been announced to the market.

Paradigm believes that one of the possible reasons for the share price spike is due to recent positive results from knee osteoarthritis (OA) patients treated with its trial drug pentosan polysulfate sodium (PPS).

READ: Paradigm Biopharmaceuticals patients report over 50% pain reduction

Of the 75 patients, 84% responded with both a reduction in joint pain and an improvement in knee function.

Notably, patients’ self-reported pain scores were reduced over 50% on average from baseline pain scores.

Paradigm will continue to report over the coming months on the groups of patients that are currently undergoing treatment under the TGA Special Access Scheme (SAS).

READ: Paradigm Biopharmaceuticals osteoarthritis clinical trial ahead of schedule

Following the trial results revealed on 15 June 2018, Paradigm chief executive officer Paul Rennie said: “The number of patients seeking treatment via the TGA SAS is accelerating, which we believe is a strong indication that the patients are receiving a clinical benefit from the iPPS treatment.

“Given these patients have a very similar treatment regimen to subjects being treated under the current phase IIb osteoarthritis randomised, double-blind, placebo-controlled, clinical trial and these patients have failed current therapies to treat OA, we feel particularly confident regarding a positive clinical trial outcome, with the expected release of headline results for that trial due in Q4 CY 2018.”

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

man coughing
November 10 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
1540445560_757z468_1537832469_knee.jpg
October 25 2018
The partnership with the US-based network will give Paradigm substantial exposure and access to a large patient pool.
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use